Optimal Hypertension Treatment for Patients with CHF and AKI

First-Line Treatment Approach

The American Heart Association recommends that patients with congestive heart failure (CHF) and acute kidney injury (AKI) should be treated with a loop diuretic, ACE inhibitor or ARB, and a beta-blocker, with careful monitoring of renal function and volume status 1, 2, 3
Loop diuretics, such as furosemide, should be used for volume control in patients with CHF and AKI, as they are more effective than thiazides in the setting of reduced renal function 1, 3
ACE inhibitors or ARBs should be used cautiously in patients with AKI, starting at very low doses with close monitoring of renal function 1, 2
Evidence-based beta-blockers, such as carvedilol, metoprolol succinate, or bisoprolol, should be included in the regimen for patients with CHF and AKI 1, 3

The American College of Cardiology recommends avoiding excessive BP reduction that could worsen renal perfusion, targeting systolic BP 120-130 mmHg rather than lower targets 2, 5

Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, should be avoided due to negative inotropic effects 1, 6
Alpha-blockers, such as doxazosin, should be avoided as they increase the risk of worsening heart failure 1, 6
Clonidine and moxonidine should be avoided in heart failure patients 1, 6
NSAIDs should be avoided as they can worsen both heart failure and kidney function 6

If BP remains uncontrolled on standard therapy, consider adding aldosterone antagonists, such as spironolactone or eplerenone, if potassium and renal function permit 1, 3
Hydralazine plus isosorbide dinitrate may be beneficial in African American patients with resistant hypertension 1, 4
For resistant hypertension after a three-drug combination, consider adding spironolactone with careful monitoring of potassium 7

Using combination RAS blockade, such as ACE inhibitor plus ARB, increases adverse events without additional benefit 4, 7